# HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients

> **NCT04986176** · PHASE3 · UNKNOWN · sponsor: **Applied Biology, Inc.** · enrollment: 602 (estimated)

## Conditions studied

- COVID-19 Respiratory Infection

## Interventions

- **DRUG:** HC-1119
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04986176
- **Lead sponsor:** Applied Biology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-15
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 602 (ESTIMATED)
- **Last updated:** 2022-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04986176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04986176, "HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04986176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*